Combined Detection Kit for Metapneumovirus and Parainfluenza Virus Antigens (Latex Chromatography Method): Technical Principles and Clinical Applications

I. Technical Principle: How Does Latex Chromatography Achieve Simultaneous Detection of Dual Targets?

Human metapneumovirus (hMPV) and parainfluenza virus (PIV) are both important pathogens causing acute respiratory tract infections in infants, the elderly, and immunocompromised individuals. Rapid clinical differentiation is often required to guide isolation and symptomatic treatment. Latex chromatography is a lateral flow detection technique based on immunolabeling and capillary chromatography principles. In this kit, two specific antibodies are pre-immobilized on a nitrocellulose membrane: an anti-metapneumovirus NP protein monoclonal antibody and an anti-parainfluenza virus (typically covering types 1-4) conserved NP protein monoclonal antibody. After the sample extraction solution is mixed with detection antibodies labeled with colored latex microspheres, it sequentially passes through the detection line via chromatography. If the corresponding viral antigen is present, an antibody-antigen-labeled antibody complex forms and develops color. Meanwhile, the control line is used to verify reagent validity. This technique features simple operation (no special equipment required) and short reaction time (generally 15-20 minutes), making it suitable for rapid screening scenarios in outpatient and emergency settings.

II. Necessity of Combined Detection: Co-infection Identification and Management of Overlapping Symptoms

Metapneumovirus and parainfluenza virus infections are highly similar in clinical presentation, both capable of causing fever, cough, wheezing, and even pneumonia, particularly as high-incidence pathogens in pediatric respiratory infections. Epidemiological data indicate that the two may exhibit seasonal overlap, and co-infection has been confirmed in some hospitalized children. If only single-pathogen testing is performed, co-infection cases are easily missed, leading to inadequate isolation management or antibiotic misuse. The antigen combined detection kit can simultaneously obtain results for both viruses through a single sampling and single operation, helping clinicians more quickly distinguish pathogen types during viral epidemic seasons, reducing unnecessary repetitive laboratory work, and providing a data foundation for multi-pathogen surveillance of respiratory infections.

III. Key Elements in Performance Verification: Sensitivity, Cross-Reactivity, and Reference Standards

In kit performance evaluation, common specification requirements include: the limit of detection generally references common viral loads in clinical samples; no cross-reactivity with other respiratory viruses of the same genus (such as respiratory syncytial virus, adenovirus, influenza virus, etc.); and evaluation of clinical sensitivity and specificity through comparison with qRT-PCR or viral culture methods. Since interfering substances (such as mucus and blood) may be present in samples containing metapneumovirus and parainfluenza virus antigens, latex chromatography kits are typically equipped with sample treatment solution to reduce interference. Additionally, kit stability—including during transport and shelf life after opening—is also a focus of medical device registration review.

IV. Clinical Application Scenarios and Potential Limitations

This kit is primarily suitable for primary care hospitals, pediatric clinics, emergency departments, and other settings where real-time nucleic acid testing cannot be performed. Its advantage of rapid results helps triage patients during peak respiratory infection seasons and enables timely contact isolation. However, it should be noted that the sensitivity of antigen testing is lower than that of nucleic acid testing, and false negatives may occur in patients with low viral loads in the early stage of illness or in immunocompromised patients. Therefore, negative results cannot completely rule out infection, and nucleic acid testing or comprehensive clinical judgment is recommended when necessary. Additionally, the kit only targets metapneumovirus and parainfluenza virus and cannot detect other mixed infection pathogens, so it should be used in conjunction with syndromic multi-target screening strategies.